Shares in Sanofi-Aventis (SASY.PA) fall 1.5 percent knocked
by comment from broker Sanford Bernstein, which says approval for a
generic version of the French drugmaker's $4 billion-a-year
anti-clotting drug Lovenox may be nearing.
"We understand that Novartis' (NOVN.VX) generic Sandoz
division, partnered with biotech company Momenta (MNTA.O), is
setting prices and soliciting pre-orders from U.S. purchasers for
its generic version of Sanofi-Aventis' Lovenox," Bernstein analysts
say in a note.
"This covert action suggests Novartis believes approval of
its generic might finally be nearing."
MNTA
Posted by hamvestor on 22nd of Jan 2010 at 11:13 am
http://uk.reuters.com/article/idUKLDE60L1JG20100122
Shares in Sanofi-Aventis (SASY.PA) fall 1.5 percent knocked by comment from broker Sanford Bernstein, which says approval for a generic version of the French drugmaker's $4 billion-a-year anti-clotting drug Lovenox may be nearing.
"We understand that Novartis' (NOVN.VX) generic Sandoz division, partnered with biotech company Momenta (MNTA.O), is setting prices and soliciting pre-orders from U.S. purchasers for its generic version of Sanofi-Aventis' Lovenox," Bernstein analysts say in a note.
"This covert action suggests Novartis believes approval of its generic might finally be nearing."
A spokesman for Novartis declined to comment.
Title: mnta I'd loosen stops on
Posted by dougwur on 22nd of Jan 2010 at 11:46 am
I'd loosen stops on this one. Potential price of $49-80 according to Dew Diligence on I-hub MNTA board. Let's hope so!